SEC Form 4 · accession 0000899243-17-024255
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony Gregg Lapointe
Director
Period of report
Oct 13, 2017
Accepted (ET)
Oct 16, 2017 · 5:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2,F1 | $1.24 | Oct 13, 2017 | D | 50,000 | D | — | Mar 30, 2019 | Common Stock | 50,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F2,F3 | $2.23 | Oct 13, 2017 | D | 5,000 | D | — | Jun 9, 2019 | Common Stock | 5,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F2,F4 | $3.01 | Oct 13, 2017 | D | 30,000 | D | — | Jun 10, 2020 | Common Stock | 30,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F2,F5 | $6.04 | Oct 13, 2017 | D | 30,000 | D | — | Jun 30, 2021 | Common Stock | 30,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F2,F6 | $6.78 | Oct 13, 2017 | D | 30,000 | D | — | Jun 7, 2022 | Common Stock | 30,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F2,F7 | $5.13 | Oct 13, 2017 | D | 30,000 | D | — | Jun 27, 2023 | Common Stock | 30,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F2,F8 | $5.10 | Oct 13, 2017 | D | 30,000 | D | — | Jun 12, 2024 | Common Stock | 30,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F2,F9 | $9.15 | Oct 13, 2017 | D | 30,000 | D | — | Jun 11, 2025 | Common Stock | 30,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F2,F10 | $10.90 | Oct 13, 2017 | D | 30,000 | D | — | Jun 8, 2027 | Common Stock | 30,000 | 0 | D |
Explanation of responses
- F1Under its terms the option became exercisable in installments at the rate of one-third of the shares subject to the option at the end of each anniversary of service as an outside director of the Issuer, beginning March 30, 2010, and became immediately exercisable and vested in full as of March 30, 2012.
- F10Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 8, 2017), and became immediately exercisable and vested in full as of the date ten (10) days prior to the Merger.
- F2The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
- F3Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 9, 2009), and became immediately exercisable and vested in full as of June 9, 2010.
- F4Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 10, 2010), and became immediately exercisable and vested in full as of June 10, 2011.
- F5Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 30, 2011), and became immediately exercisable and vested in full as of June 30, 2012.
- F6Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 7, 2012), and became immediately exercisable and vested in full as of June 7, 2013.
- F7Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 27, 2013), and became immediately exercisable and vested in full as of June 27, 2014.
- F8Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 12, 2014), and became immediately exercisable and vested in full as of June 12, 2015.
- F9Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016.